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Abstract
Background: The poor response to antiviral treatment
of hepatitis C virus (HCV)-infected patients with geno-
type 1b has been associated with a higher prevalence
of metabolic syndrome. However, the molecular link
between these clinical entities is not clear. The goal
of this study was to clarify the role of genotype 1b
and 2 in the genetic expression of suppressor of cyto-
kine signaling 3 (SOCS3) and insulin receptor sub-
strate 1 (IRS-1).
Methods: We infected human hepatocellular carcino-
ma cell line (HepG2) cells with human HCV genotype
1b or 2 and measured the gene and protein expres-
sion of SOCS3 at various times. We also evaluated
impairment in the insulin pathway by analysis of IRS-
1 and phospho-AKT. For the control, we used HepG2
cell cultures treated with non-infectious serum. We
also demonstrated the occurrence of HCV infection by
the detection of both positive and negative strands in
the cells and culture medium. To test infection of the
HepG2 cells, we performed quantitative real-time
polymerase chain reaction (qRT-PCR) of viral load at
different time points. We analyzed the viral genotype
in the pellet and supernatant.
Results: At each time point, we found positive and
negative strands in the infected cells, while in the
medium we found positive, but no negative strands.
We also detected the presence of the correct geno-
type in the medium. Two weeks following infection
when the viral load was higher, we tested genotype
1b and 2 infected cells. SOCS3 gene expression was
significantly higher in genotype 1b-infected cells
(median 2.56; mean 2.82"0.59) compared with geno-
type 2 (median 1.34; mean 1.46"0.31) (ps0.04) and
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control cells (median 1.09; mean 1.02"0.11, ps0.02).
There was no difference between cells exposed to
genotype 2 and control cells. Conversely, IRS-1 was
significantly lower in genotype 1b-infected cells
(median 15.97; mean 15.45"0.67) compared with
genotype 2-infected cells (median 16.45; mean
16.44"0.01, ps0.04). Statistically significant differ-
ences were seen when comparing the pAKT/AKT ratio
in genotype 1b-infected cells (0.19"0.034) and not
genotype 1b-infected (genotype 2-infected and non-
infected) cells (0.253"0.004, ps0.03). This inverse
regulation is compatible with interactions between
the molecular expression of SOCS3, IRS-1 and phos-
pho-AKT mediated by the genotype 1b virus.
Conclusions: Up-regulation of the SOCS3 gene might
be one of the mechanisms governing non-response
to therapy and expression of insulin resistance medi-
ated via a direct mechanism at this level of genotype
1b HCV.
Clin Chem Lab Med 2009;47:1217–25.
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Introduction
Therapy with peginterferon a and ribavirin is the stan-
dard of care for hepatitis C virus (HCV)-related chronic
hepatitis (1, 2). This treatment results in a high per-
centage of sustained response and depends primarily
on the type of infection; 90% in genotype 2 viral infec-
tion and 50% in genotype 1 viral infection (3). We pre-
viously identified a link between the response to
antiviral treatment of HCV-related liver disease and a
variety of genes, some of which are up-regulated and
others down-regulated (4). Recently, we found that
the suppressor of cytokine signaling 3 (SOCS3) gene,
which affects the insulin pathway, was over-expressed
in non-responding patients with genotype 1b HCV
compared with patients with genotype 2 HCV. Also,
the clinical expression of insulin resistance was sig-
nificantly higher in patients with genotype 1 (5). Alter-
ations in the insulin receptor substrate 1 (IRS-1) may
induce insulin resistance via defects in intracellular
transduction signaling (6).
SOSC3 expression has been found to be increased
in liver tissue from patients with chronic genotype 1
HCV infection who did not respond to treatment (7).
Huang et al. (8) confirmed this finding in cell cultures
and chimpanzees. They postulated that HCV affects
SOCS3 expression by stimulating cytokines, such as
TNF-a and IL-10. Subsequently, we showed that up-
regulation of SOCS3 in non-responding patients is
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Figure 1 Nested RT-PCR amplification of viral sense and
anti-sense HCV strands.
(A) HCV-RNA extracted from HepG2 inoculated with HCV-
infected sera was amplified with specific primers to obtain a
fragment of 154 bp in positive samples for both sense strand
(from lane 2 to lane 6) and anti-sense strand (from lane 9 to
lane 13). Lanes 1 and 8 represent culture cells treated with
non-infectious serum and lanes 7 and 14 H2O. (B) HCV-RNA
was extracted from culture medium of HepG2 cells inoculat-
ed with HCV-infected sera at various time points during
infection. Nested RT-PCR showed the presence of sense
strand (from lane 2 to lane 5) in culture medium, whereas
no signal was detected in the presence of anti-sense strand
(from lane 7 to lane 10). Lane 1 represents culture cells treat-
ed with non-infectious serum.
related to a peculiar polymorphism of the gene,
namely, –4874 A/G (9).
The goal of this study was to verify the in vitro
effect of HCV on SOCS3 overexpression in order to
determine whether the level of SOCS3 expression dif-
fers between infection with HCV genotype 1 and 2,
and whether this difference might interfere with the
protein concentrations of IRS-1.
Materials and methods
Viral inoculation and sample collection
Human hepatocellular carcinoma cell line (HepG2) culture
and infection were performed as described previously
(10–12). For infection of serum, 50 mL of patient serum was
diluted in 1.5 mL of medium and added to cells plated in
35 mm dishes. Following an overnight incubation, the cells
were rinsed 6–10 times with phosphate buffered saline (PBS)
and 2 mL of fresh growth medium was added. The final
wash was collected for HCV testing (shown as time 0 in the
Figures). Cells were grown for 48 h to semi-confluence in
complete medium, washed twice with fetal bovine serum
(FBS)-free medium, then inoculated with serum samples
from four patients infected with HCV genotype 1b, four
patients with HCV genotype 2 wreal-time polymerase chain
reaction (RT-PCR) and antibody positivex, and four healthy
subjects who served as negative controls (500 mL serum and
500 mL FBS-free Dulbecco’s modified Eagle medium
wDMEMx/3=106 cells). The HCV genotypes were character-
ized as genotype 1b and genotype 2 as previously reported
(5, 13). The viral load in sera was quantified using RT-PCR,
and the average copy number was 1.9=105 copies/L. After
90 min, DMEM (GIBCO-Invitrogen, Milan, Italy) containing
10% FBS (Celbio, Milan, Italy) was brought to a final volume
of 8 mL, including the volume of human serum used for
infection as reported above. Cells were maintained overnight
at 378C in 5% CO2. The following day, adherent cells were
washed three times with culture medium to remove any
remaining serum, and cell growth was continued for 4 weeks
in complete medium containing 10% FBS, with a change of
medium every 3 days. Cells and supernatant were collected
on day 3, and 1, 2, 3 and 4 weeks after inoculation with HCV.
The cellular level of viral infection was quantified at the var-
ious time points with RT-PCR amplification of sense and anti-
sense strands. Genotyping analysis was also performed at
these same points and genotypes were tested on the cells
and culture medium.
Extraction and quantification of HCV-RNA
HCV-RNA was isolated from HepG2 cells using the guanidi-
nium isothiocyanate method with TRIzol reagent (Invitrogen,
Milan, Italy) (14), and from 200 mL of culture medium and
200 mL of serum using High Pure Viral RNA Kit (Roche Diag-
nostics, Milan, Italy).
Extracted RNA was amplified and quantitated using
sequence-specific hybridization probes with the Reaction
Mix LightCycler RNA Master HybProbe (03018954001 –
Roche Diagnostics, Milan, Italy) with the LightCycler system
(Roche Diagnostics, Milan, Italy). The amplification primers
are located in the highly conserved 59 untranslated (UTR)
region of the HCV genome, which identifies an amplicon of
244 bp. Their sequences are: sense 59-CTC gCA AgC ACC
CTA TCA ggC AgT-39 and antisense 59-gCA gAA AgC gTC
TAg CCA Tgg CgT-39 (TIB MOLBIOL, Berlin, Germany).
The sequences of hybridization probes are: the donor
probe 59-gCA gCC TCC Agg ACC CCC C-39 labeled with 5,6-
carboxylfluorescein attached to 39-O-ribose. The adjacent
acceptor probe 59-CCC ggg AgA g CC ATA gTg gTC Tg-39 is
labeled with LightCycler Red 640 attached to the 59 terminus
(both from TIB MOLBIOL, Berlin, Germany). Following
hybridization to the template DNA, the two probes are in
close proximity resulting in fluorescence resonance energy
transfer (FRET) between the two fluorophores. The emitted
fluorescence of the LightCycler Red 640 is then measured
with the LightCycler Instrument. The RT-PCR reaction was
performed in a final volume of 20 mL, with 8 mL of RNA. The
thermal profile was 30 min at 618C, 958C for 30 s, followed
by 45 cycles of 1 s at 958C, 10 s at 568C, and 1 s and 13 s at
728C. An external standard curve to quantify the HCV
genomes present in the sample was constructed using a
control target 59UTR fragment cloned from patients infected
with HCV (15).
The assay targets the 59-UTR region, and the primers are
also used in the Amplicor system. The detection limit of the
assay was 10 IU/mL, corresponding to ;25 copies/mL
(according to the WHO, 1 IU corresponds to 2–5 genome-
copies, depending on the HCV-RNA method).
PCR on HCV genomic RNA strands
Extracted RNA was analyzed using a strand-specific reverse
transcriptase (RT)-nested PCR assay with Tth DNA Polymer-
ase for positive and negative strands of HCV-RNA. In the
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Figure 2 Viral load in HepG2 cells performed with qRT-PCR.
Monitoring of infection in HepG2 cells treated with HCV
infected sera of both genotype 1b and genotype 2. Viral lev-
els were monitored periodically showing fluctuations in viral
load ranging from 80 copies/mL to 6.7=106 copies/mL.
Figure 3 Genotyping of HepG2 cells and culture medium with Inno Lipa 2.0 Kit.
The Versant HCV genotype 2.0 Assay (LiPA) uses a biotinylated DNA PCR product specific to the 59UTR and core region of
the HCV genome. (A) a: the strip identifying probes that hybridize the PCR product of serum samples with genotype 1b HCV;
b: the reading card to report data; c: the strip identifying probes that hybridize the PCR product of serum samples with
genotype 2 HCV. (B) Presence of genotype in the cells and culture medium. Strips 1–3 represent respectively genotype 1b
and 2 detected in the cells; strips 2–4 represent respectively genotype 1b and 2 detected in culture medium. Genotyping was
done at every time point and for every cell culture.
sense strand HCV-RNA assay, 0.5 mg of cellular RNA (cor-
responding to ;6=105 cells) in 10 mL of diethyl pyrocarbo-
nate-treated water was heated at 708C for 5 min and then
immediately placed on ice. A 10-mL reaction mixture con-
taining five units of Tth DNA Polymerase (Promega, Milan,
Italy), 1X RT Buffer (Promega, Milan, Italy), 1 mM MnCl2, in
a final concentration of 0.2 mmol/L from each dNTP (Invitro-
gen, Milan, Italy), and 50 pmol of the reverse primer P1 was
prepared for cDNA synthesis. Primer annealing was per-
formed at 588C for 2 min, followed by the RT reaction at
658C for 30 min. To inactivate the RT activity of Tth, 30 mL of
PCR mixture containing 8 mL of 10X buffer to chelate
Mn2q, 50 pmol of the forward primer P2 and 3.75 mM MgCl2
was added. PCR was performed using the GeneAmp PCR-
System 9600 apparatus (Applied Biosystems, Branchberg,
NJ, USA). The reaction mixture was initially kept at 948C for
1 min for enzyme activation, followed by 40 amplification
cycles. Each cycle consisted of denaturation at 948C for 30 s,
primer annealing at 588C for 30 s, and primer extension at
728C for 30 s. This was then followed by a final extension
step at 728C for 7 min. PCR products were analyzed using
agarose gel electrophoresis. The anti-sense strand HCV-RNA
assay was performed using the same procedure except that
the primers were used in reverse order. A 299-bp fragment
was identified in positive samples. The second round of
amplification was performed like the first round, except for
the use of 50 pmol of the nested reverse primer P3 and
50 pmol of the forward primer P4. A 154-bp fragment was
identified in positive samples. Primer sequences were: P1: 59
ggT gCA Cgg TCT ACg AgA CCT C 39; P2: 59 AAC TAC TgT
CTT CAC gCA gAA 39; P3: 59 TgC TCA Tgg TgC ACg gTC TA
39; P4: 59 ACT Cgg CTA gCA gTC TCg Cg 39. All PCRs were
performed in duplicate. Amplified products were analyzed
using electrophoresis with a 2% agarose gel and stained
with Vistra Green nucleic acid. The same gel was scanned
with STORM 860 to 450 nm (Molecular Dynamics, GE Health-
care Europe GmbH, Milan, Italy) (16, 17).
HCV genotyping of infected cells
RNA extracted from HepG2 cells and culture medium was
used for genotyping. Using reverse primer P1 in the RT step,
cDNA copies were generated from viral RNA. The cDNA was
amplified using PCR with outer primers in the first round and
inner primers in the second round contained in the HCV Geno-
type Amplification kit (LIPA – SIEMENS, Bayswater VIC, Aus-
tralia). DNA products were amplified and biotinylated in the
Versant HCV genotype assay (LIPA – SIEMENS, Australia)
(18).
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Figure 4 SOCS3 gene expression in genotype 1b, genotype 2 and control HEPG2 cells.
(A) SOCS3 gene expression profile at day 3, and 1, 2, 3 and 4 weeks after inoculation with HCV-infected sera. (B) After 2
weeks of HCV infection, SOCS3 gene expression was significantly up-regulated in HepG2 cells infected with HCV genotype
1b vs. cells with genotype 2 (Mann-Whitney test; *ps0.04) and non-infected cells (Mann-Whitney test; **ps0.02). (C) Mx-A
gene expression 2 weeks after HCV infection. Data are presented as medians and means"SEM.
RNA isolation, RT-PCR and quantitative real-time
(qRT)-PCR analysis of SOCS3, Mx-A and IRS-1
Total cellular RNA was extracted from the cultured cells
using the guanidinium isothiocyanate method with the TRI-
zol reagent (Invitrogen, Milan, Italy) (19). All RT reactions
were performed using the iScript cDNA synthesis kit
(BioRad, Milan, Italy), according to the manufacturer’s
instructions. qRT-PCR was performed using the SYBR Green
PCR Master Mix with the Applied Biosystem Model 7900HT
Sequence Detection System. The primers were designed
by the Primer Express 2.1 program (Applied Biosystems,
Branchberg, NJ, USA). Primer sequences are as follows:
SOCS3, forward 59-CTTTCTGATCCGCGACAGCT-39, reverse
59-TGGTCCCAGACTGGGTCTTG-39; Mx-A, forward 59-GGAG-
GAGATCTTTCAGCACCTG-39, reverse 59-TGGATGATCAAA-
GGGATGTGG-39; IRS-1, forward 59-GCCAGAGGACCGTCA-
GTAGCT-39, reverse 59-AGGATTTGCTGAGGTCATTTAGGT-39.
All PCRs were performed in duplicate. b-Actin (forward
59-CGTGCTGCTGACCGAGG-39, reverse 59-GAAGGTCTCAAA-
CATGATCTGGGT-39) was used as internal control.
Western blotting
Harvested cells were washed three times with ice-cold PBS
and homogenized with ice-cold buffer for extracting the cyto-
solic fraction at 48C w10 mM HEPES, pH 7.9, 1.5 mM MgCl2,
1 mM EDTA, 0.5 mM DTT, 10% (v/v) glycerol and a complete
protease inhibitor cocktail (Roche Diagnostics, Milan, Italy)x.
Protein content was measured with the Bradford assay
(BioRad, Milan, Italy). Using the method of Laemmli (20),
30 mg of cytosolic lysate was loaded onto two different
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Table 1 SOCS3 gene expression analysis in all experimental points.
Collection SOCS3 mRNA levels wmean (SE); medianx p-Valuea p-Valueb
points
Negative Genotype 2 Genotype 1b
3 days 1.08 (0.27); 1.26 1.02 (0.09); 1.08 0.73 (0.06); 0.73 N.S. N.S.
1 week 1.08 (0.24); 0.96 1.25 (0.19); 1.11 1.66 (0.40); 2.03 N.S. N.S.
2 weeks 1.02 (0.11); 1.09 1.46 (0.31); 1.34 2.82 (0.59); 2.56 0.04 0.02
3 weeks 1.00 (0.05); 0.98 0.80 (0.07); 0.82 0.93 (0.12); 0.99 N.S. N.S.
4 weeks 1.14 (0.37); 0.89 1.36 (0.17); 1.39 1.10 (0.12); 1.07 N.S. N.S.
aComparison between cell lines infected by HCV genotype 2 vs. genotype 1b; bcomparison between cell lines infected by HCV
genotype 1b vs. those treated with negative sera Mann-Whitney test. SOCS3, suppression of cytokine signaling 3; SE, standard
error; N.S., not significant.
Figure 5 Levels of the SOCS3 protein in HepG2 2 weeks
after HCV infection.
(A) Western blot of SOCS3 and b-actin in HepG2 cells inoc-
ulated with serum from 3 HCV genotype 1b- and 3 HCV
genotype 2-infected patients; 3 healthy, HCV-negative sub-
jects served as negative control. (B) The protein level was
significantly higher in cells infected with HCV genotype 1b
vs. cells infected with HCV genotype 2 (Mann-Whitney test;
*ps0.04) and non-infected cells (Mann-Whitney test;
**ps0.03). Data are presented as median and mean"SEM.
OD, optical density.
polyacrylamide gels: 12% for SOCS3 protein, 6% for IRS-1
protein and 10% for AKT and phospho-AKT (Ser473) pro-
teins. Western blotting was performed as described else-
where (21) with a specific mouse anti-SOCS3 antibody
(1:500) (BioLegend, San Diego, CA, USA), a specific rabbit
anti-IRS-1 (1:500), a specific rabbit anti-AKT (1:1000) and
phospho-AKT (Ser473) (1:500) (Cell Signaling Technology,
Danvers, MA, USA). Goat anti-b-actin antibody (1:1000) (San-
ta Cruz Biotechnology, Santa Cruz, CA, USA) was used as
the control for equal loading. Semiquantitative analysis of
protein expression was performed. The bands were quanti-
fied by densitometry to obtain an integral optical density val-
ue, which was then normalized with respect to the b-actin
value. We used the GS-800 Calibrated Densitometer and the
Quantity One 4.6.3 program (BioRad, Milan, Italy) for densi-
tometric analyses.
Gene and protein expression analysis
For qRT-PCR data, the mean fold changes2–(average DDCt) was
calculated using the mean difference in the DCt between the
genes and the internal control. The DCt was calculated using
the differences in the mean Ct between selected genes and
the internal control. Ct indicates the cycle threshold, the frac-
tional cycle number where the fluorescent signal reaches the
detection threshold (22). The significance of difference in
protein and gene expression was determined using the
Mann-Whitney or Student t-tests. A p-0.05 was used for
statistical significance.
Results
HCV replicates in HepG2 cells infected in vitro
HCV infection was monitored using nested RT-PCR
amplification of viral sense and anti-sense HCV
strands. Figure 1A shows HCV infection in HepG2
cells; both positive and negative HCV-RNA strands
were found in cell pellets. To verify infection, we per-
formed the same experiment with the culture medi-
um. As shown in Figure 1B, positive HCV-RNA strand
appeared, but, as expected, the negative strand did
not (Figure 1B). Similar results were obtained with
HCV genotype 1- and 2-infected cells at each reported
time (see ‘‘Materials and methods’’). Following treat-
ment with HCV positive sera and negative sera, we
monitored infection in the cultures with qRT-PCR for
28 days. HCV-RNA shows a cyclical pattern, with
peaks at 3, 14, 28 days following infection (Figure 2).
Fluctuations in HCV levels were observed in both cul-
tures infected with genotype 1b and genotype 2 sera.
HCV levels in the cultures reached high concentra-
tions, ranging from 105 to 107 copies/mL during the 4
weeks culture period. Also, we used the genotyping
hybridization method as the control for the experi-
ment and infection. Figure 3 shows data documenting
the genotype 1b and 2 infection of sera used for
HepG2 cells incubation (panel A), and for supernatant
and cell cultures (panel B).
SOCS3 gene expression and protein levels
in HepG2 cells infected in vitro
We measured SOCS3 gene expression by qRT-PCR in
HepG2 cells at day 3, and 1, 2, 3 and 4 weeks follow-
ing inoculation with HCV (Figure 4A). SOCS3 gene
expression did not differ significantly between cell
lines infected with HCV genotype 1b and those infect-
ed by HCV genotype 2, nor did they differ between
HCV genotype 1b-infected cells and cells treated with
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Figure 6 Insulin receptor substrate 1 (IRS-1) gene expression and protein level in HepG2 infected cells.
(A) IRS-1 gene expression 3 days and 2 weeks after HCV infection. (B) Levels of the IRS-1 protein in HepG2 2 weeks after HCV
infection. (C) The IRS-1 protein level was significantly lower in cells infected with HCV genotype 1b vs. cells infected with
HCV genotype 2 (Mann-Whitney test; *ps0.02) and vs. non-infected cells (Mann-Whitney test; ps0.02). The y-axis shows the
optical density (OD) of the IRS-1 expression. Data are presented as median and mean"SEM.
healthy control sera, at day 3, and 1, 3 and 4 weeks
following inoculation with HCV (Table 1). Two weeks
following HCV infection, SOCS3 mRNA levels were
significantly higher in cells infected with HCV geno-
type 1b (median 2.56; mean 2.82"0.59) vs. cells
infected with genotype 2 (median 1.34; mean 1.46"
0.31, ps0.04) and vs. cells that were not infected
(median 1.09; mean 1.02"0.11, ps0.02) (Figure 4A
and B). Genotype 2 cells did not differ from control
cells. There was an inverse relationship between
SOCS3 gene expression and the expression of Mx-A
(Figure 4C), which is consistent with previous data (9).
In particular, Mx-A was down-regulated significantly
in HepG2 cells infected with HCV genotype 1b (medi-
an 0.76; mean 0.77"0.05) compared with cells infect-
ed with genotype 2 (median 1.04; mean 1.04"0.01,
ps0.02) and cells that were not infected (median 1.03;
mean 1.01"0.06, ps0.04). Western blot analysis con-
firmed that SOCS3 protein levels were significantly
higher in cells infected with genotype 1b (median
16.68; mean 16.67"0.01) with respect to genotype 2
(median 16.48; mean 16.48"0.02, ps0.04) and con-
trol cells (median 16.19; mean 16.26"0.13, ps0.03)
(Figure 5A and B).
IRS-1 gene expression and protein levels
in HepG2 cells infected in vitro
We analyzed IRS-1 gene expression and IRS-1 protein
levels in genotype 1b- and 2-infected cells at 3 days
and 2 weeks following infection with HCV. SOCS3
expression peaked 2 weeks following infection with
genotype 1-infected HepG2 cells (Figure 1). IRS-1
expression, measured with qRT-PCR, did not differ
between genotype 2- and genotype 1b-infected cells
(Figure 6A). Conversely, when measured with West-
ern blotting, the IRS-1 protein level was significantly
lower in genotype 1b-infected cells (median 15.45;
mean 15.47"0.03) than in cells infected with HCV
genotype 2 (median 16.60; mean 16.59"0.01, ps0.02)
(Figure 6B and C). Of note, there was no difference in
protein levels between HepG2 cells infected by HCV
genotype 2 and cells that were not infected (ps0.15).
AKT protein levels in HepG2 cells infected in vitro
We analyzed the protein level of AKT and its phos-
phorylation state (pAKT) by Western blotting (Figure
7A) using the same samples that had been analyzed
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Figure 7 AKT and phospho-AKT (Ser473) protein levels in HepG2 infected cells.
(A) Levels of the AKT and phospho-AKT proteins in HepG2 2 weeks after HCV infection. (B) The pAKT/AKT ratio was signifi-
cantly lower in genotype 1b-infected cells vs. cells not infected with genotype 1b (genotype 2-infected and not infected) cells
(Student t-test, *ps0.03). The y-axis shows the optical density (OD) of the phospho-AKT expression compared to AKT protein.
Data are presented as median and mean"SEM.
for IRS1 and SOCS3 expression. We observed a
reduction of pAKT/AKT ratio in genotype 1b-infected
cells when compared to genotype 2-infected cells
(25.9%) and cells that were not infected (21.9%). A sta-
tistically significant difference was observed when
comparing the pAKT/AKT ratio in genotype 1b-infect-
ed cells (0.19"0.034) and cells not infected with gen-
otype 1b (genotype 2-infected and not infected) cells
(0.253"0.004, ps0.03) (Figure 7B).
Discussion
To evaluate if the HCV genotype affects the molecular
expression of SOCS3, we reproduced genotype 1 and
2 virus infection in HepG2 cells. We used HepG2 cells
rather than a lymphoblastoid cell line because their
biosynthetic pathway is similar to that of hepatocytes
(22), and because overexpression of SOCS1 and
SOCS3 in human hepatoma HepG2 cells suppresses
IFN-a-induced STAT activation and gene expression
of the antiviral proteins 29,59 OAS (29-59-oligoadenylate
synthetase and MxA (21). In addition, lymphoblastoid
lines immortalized by Epstein-Barr virus interferes
with HCV infection. Finally, propagation of HCV in
HepG2 cells has been well validated (10, 23). We inoc-
ulated HepG2 cells with either genotype 1 or geno-
type 2 according to La´zaro et al. who reported that
serum infected cells still showed high virus titers up
to 2 months in both the cell pellet and the culture
medium (12). In our system, cells showed fluctuating
virus levels up to 30 days and greater (data not
shown), in a cyclic pattern with peaks at 4, 15 and
24 days. This may reflect the effect of host responses
to the virus as reported by others (12, 24, 25). More-
over, the analysis of genotypes by reproducing the
genotype specific infection in both cell culture and
culture medium also confirms that our system is able
to support viral replication.
After 2 weeks of viral exposure, SOCS3 expression
was significantly higher in cells infected with geno-
type 1b vs. cells infected with genotype 2, and also
vs. non-infected cells. There was no difference
between genotype 2-infected and non-infected cells.
Of interest was the ‘‘mirror effect’’ during the peak of
viremia, SOCS3, IRS-1 and AKT in genotype 1-infect-
ed cells. Namely, the HCV-RNA peak was associated
with a significant increase in SOCS3 and a significant
decrease in the intracellular levels of IRS-1 and pAKT.
This observation is in agreement with the finding that
SOCS3-related IRS-1 degradation occurs via the ubi-
quitin system (22, 23). Moreover, the reduction in AKT
phosphorilation confirms the altered intracellular
insulin metabolic pathway, and supports the idea that
genotype 1b HCV might somehow interfere at this lev-
el. The inverse regulation between SOCS3 and IRS-1
suggests that genotype 1b HCV affects the expression
of SOCS3 and IRS-1. These results are in agreement
with our previous report of enhanced SOCS3 in non-
responding patients with genotype 1 HCV infection
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(5), and supports the concept that virus-related
SOCS3 gene up-regulation underlies the non-
response to therapy and the clinical expression of
insulin resistance in genotype 1-infected patients.
Pazienza et al. (23) reported significantly greater
insulin resistance in genotype 1 patients, and found
that the mechanism underlying IRS-1 down-regula-
tion was not related to SOCS3. Our data do not sup-
port this observation, and instead support the finding
that the HCV down-regulates IRS-1 and 2 by up-reg-
ulating SOCS3 (26). Moreover, our finding supports
the concept that the IFN-a antagonistic activity of HCV
core protein involves SOCS3 induction (27). This is
consistent with the association between lack of
response to antiviral therapy and obesity and hepatic
expression of SOCS3 in genotype 1 patients (6). How-
ever, insulin resistance is a predictor of sustained
viral response in patients that respond to treatment
(genotype 2 and 3) (28). The apparent discrepancy
between this observation and our data could be that
non-responding patients infected with ‘‘easy’’ geno-
types might have a SOCS3 polymorphism that results
in higher levels of SOCS3. This fact, together with jak/
stat suppression, might interfere with the insulin
intracellular pathway. Further studies are needed to
address this hypothesis.
In conclusion, we demonstrate that genotype 1b
HCV plays a crucial direct role in up-regulation of the
SOCS3 gene, conditioning the response to antiviral
therapy and expression of insulin resistance. This
observation challenges the concept that the response
to therapy is governed by insulin resistance. Further
studies on the biological mechanism underlying the
interaction between HCV and SOCS3 might lead to
new combinations of therapeutic strategies that are
effective in patients who do not respond to traditional
therapy.
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